作为癌症免疫治疗的载体。
as a Vector for Cancer Immunotherapy.
作者信息
Leitão Jorge H
机构信息
IBB-Institute for Bioengineering and Biosciences, Department f Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, Torre Sul, Piso 6, 1049-001 Lisboa, Portugal.
出版信息
Vaccines (Basel). 2020 Aug 5;8(3):439. doi: 10.3390/vaccines8030439.
Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by , the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, , 48) on the use of as a vector for cancer immunotherapy is described and commented here.
癌症是一大类疾病，2018年有960万人死于癌症。癌症免疫疗法已成为现实，2010年首次批准了用于前列腺癌治疗的西妥昔单抗。 是一种革兰氏阳性菌，主要作为食源性病原体为人所知，能够引起危及生命且往往致命的感染。然而，由于在大多数情况下，人类免疫系统能够产生强大的先天性和适应性免疫反应来控制由 引起的感染，这种微生物已成为癌症疫苗开发的有吸引力的载体。本文描述并评论了小弗利金格、罗德克和斯诺克（《疫苗》2018年， ，48）关于 使用 作为癌症免疫治疗载体的综述。 （注：原文中部分内容缺失，翻译时保留了原文格式）
Zotero 插件